AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01344135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on physical activity level
Description: Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle
Study NCT03925896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP2 Antigen-specific TCR T cells
Description: All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
Study NCT00486681 — intervention group
Intervention type: DEVICE
Intervention: Accu Chek Inform and Cobas IT 1000
Description: period II (warning activated)
Study NCT02265965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous nitroglycerin
Description: Infusion at started at time of hysterotomy and stopped at neonate delivery
Study NCT04583982 — intervention group
Intervention type: OTHER
Intervention: T-Detect™ SARS-CoV-2 Assay
Description: T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
Study NCT00060411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given IV
Study NCT00060411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00060411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00060411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00060411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00207740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO148
Description: Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
Study NCT00207740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
Study NCT02332265 — intervention group
Intervention type: OTHER
Intervention: Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)
Description: The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
Study NCT02390232 — intervention group
Intervention type: BIOLOGICAL
Intervention: liver biopsy
Description: A small needle is inserted into the liver to collect a tissue sample
Study NCT02390232 — intervention group
Intervention type: BIOLOGICAL
Intervention: collection of stools
Description: collection of stools
Study NCT02390232 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: collection of blood sample
Study NCT02305264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DPA-714 and 18F-FDG
Description: Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter.
Study NCT03881436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with DTI sequence
Description: At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence
Study NCT03055936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa 50 mg or 100 mg or 150 mg
Study NCT03055936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Carbidopa 12.5 mg or 25 mg or 65 mg
Study NCT03055936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-104
Description: ODM-104 50 mg or 100 mg
Study NCT00128128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
Study NCT00128128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
Study NCT03207399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epclusa
Description: Patients will be treated with this drug for 12 weeks post lung transplant.
Study NCT02552927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest shield with aluminum foil (CALF)
Study NCT02552927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHIELD
Study NCT04739228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Written Disclosure Protocol Group
Description: The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
Study NCT04739228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
Study NCT00835718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 5 mg/day
Description: MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
Study NCT00835718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 1 mg/day
Description: MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Study NCT00835718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 1 mg/week
Description: MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Study NCT00835718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MK0594
Description: Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
Study NCT03812419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
Study NCT03812419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
Study NCT01836237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis - a wound protector
Description: Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
Study NCT02073786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lightwand intubation
Description: Conventional lightwand intubation technique will perform during intubation
Study NCT02073786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid video stylet
Description: Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
Study NCT02536911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00599560 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: vasopressin, V2 receptor and cyclic AMP
Description: plasma vasopressin, V2 receptor, cyclic AMP
Study NCT04620499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: PEER EEG
Study NCT02457975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670nm PBM
Description: Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
Study NCT02457975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreous VEGF-inhibitors
Description: Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
Study NCT02457975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreous VEGF-inhibitors
Description: Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
Study NCT04463134 — intervention group
Intervention type: DRUG
Intervention: NTM drug treatment
Description: NTM drug treatment according to guideline and sensitivity test results
Study NCT02051868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
Study NCT02051868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
Study NCT02051868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
Study NCT02051868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
Study NCT00477009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance, adjustable
Description: Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
Study NCT00477009 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mandibular repositioning appliance, adjustable
Description: Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
Study NCT00496418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh in permanent colostomy
Study NCT00496418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh in permanent colostomy
Study NCT01417169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
Study NCT00706563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Single intramuscular dose on Day 0
Study NCT03311191 — intervention group
Intervention type: DEVICE
Intervention: Measurement of skin oxygenation and oxygen consumption
Description: Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
Study NCT03071601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine Cream 2.5-2.5%
Description: Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
Study NCT03071601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Epinephrine 0.005mg/mL solution
Description: Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
Study NCT00251758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Study NCT00251758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
Study NCT00251758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study NCT02727712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral thoracic paravertebral block
Description: group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4)program
Study NCT02727712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transesophageal Echocardiography（TEE）
Description: 1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management
Study NCT02727712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography（TEE）
Description: 1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management
Study NCT02727712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung protection measure during the surgery（Dräger Primus）
Description: Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
Study NCT02727712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung protection measure during the surgery（Dräger Primus）
Description: Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
Study NCT02727712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia drugs during the surgery
Description: 1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.
Study NCT02727712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia drugs during the surgery
Description: 1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.
Study NCT02727712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: group B under(TPVB T3/4)by ropivacaine(0.3%,20ml\*2)program
Study NCT04087512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on perturbation treadmill
Description: Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
Study NCT04087512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises of dynamic stability under unstable conditions
Description: The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
Study NCT04366674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleft palate repair
Description: restoration of tensor veli palatini for the purpose of the muscle function recovery.
Study NCT04366674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleft palate repair
Description: restoration of tensor veli palatini for the purpose of the muscle function recovery.
Study NCT04596904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil application group
Description: Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
Study NCT04596904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water application group
Description: Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
Study NCT02865863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eurycomalongifoliawater extract (Physta®)
Study NCT02865863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02865863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Study NCT04600349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Oriented Psychotrauma Therapy
Description: The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
Study NCT04600349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study NCT05005598 — intervention group
Intervention type: OTHER
Intervention: catheter dysfunction
Description: prevalence of catheter dysfunction